Key result
Serial cardiac magnetic resonance imaging in a mouse model demonstrated that while dexrazoxane did not prevent initial doxorubicin-induced myocardial edema, it minimized subsequent cardiac dysfunction and fibrosis.
Why the study?
Identification of early markers of myocardial damage secondary to anthracycline exposure is crucial to develop strategies that may ameliorate cancer therapy-related cardiac dysfunction.
Does dexrazoxane prevent early myocardial changes induced by doxorubicin as detected by serial CMR in a mouse model?
Population
90 mice
Comparison
Doxorubicin alone vs doxorubicin with dexrazoxane vs saline
Design
Pre-clinical animal study
Authors
Loading...
Animal model CMR findings are hypothesis-generating; leaves open translation to pediatric cancer survivors.
Does dexrazoxane prevent early myocardial changes induced by doxorubicin as detected by serial CMR in a mouse model?
Serial CMR, particularly T2 mapping and deformation, can detect early anthracycline-induced myocardial injury and demonstrates that dexrazoxane minimizes sustained inflammatory changes and cardiac dysfunction in a mouse model.
Noel et al. (2021) studied Cancer therapy-related cardiac dysfunction (Doxorubicin-induced cardiotoxicity) (n=90). Doxorubicin with and without dexrazoxane vs. Saline injection was evaluated on Presence of ventricular dysfunction (decrease in LVEF or RVEF below 50%). Serial cardiac magnetic resonance imaging in a mouse model demonstrated that while dexrazoxane did not prevent initial doxorubicin-induced myocardial edema, it minimized subsequent cardiac dysfunction and fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: